Characterization of the Effect of Camelid Wnt16B Antibody Treatment on Mammalian Cancer Cell Lines
The projects aims to develop a method to block the Wnt16B protein known to cause cancer growth and development by using target specific Camelid IgG antibodies in cancer cell culture that overexpresses Wnt16B. The Camelid antibodies programed to block the Wnt16B protein will be assessed for efficiency on how well they are able to block the effects that Wnt16B has on cancer cells. Cancer cell proliferation changes will be analyzed to assess the effects the target specific Camelid antibodies against WNT16B has on cancer cells. The partner organization, CamOleum Inc. has an international patent in using Camelid antibodies in cancer immunotherapy, in which will be expanded on by this project. CamOleum Inc. will benefit from this research as there is already a provisional patent put in place for this project that will be expanded upon attaining data from the lab.
View Full Project DescriptionJohn Hudson
CamOleum Inc.
Life Sciences
Retail trade
University of Windsor
Accelerate
